That blockbuster anti-NGF pain drug fulranumab? J&J doesn't want it anymore

J&J CEO Alex Gorsky

Back in early 2015, J&J ($JNJ) CEO Alex Gorsky tapped the Phase III anti-NGF pain drug fulranumab as one of the pharma giant's top 10 new drug prospects, a key asset in the company's game plan for achieving growing drug sales. On Thursday evening, J&J swept the one-time heavyweight contender out the back door with barely a comment.

Currently in four big studies, according to clinicaltrials.gov, J&J has decided to hand it all back to Amgen ($AMGN), where it found the drug in 2008 and licensed rights to it in a $435 million pact. Years of trial expenses and blockbuster hopes that once pegged the anti-NGF class as an $11 billion market in the making--before a safety disaster blighted the field in 2012 and forced a slow comeback effort--have been written off.

"This decision was based on strategic portfolio prioritization and was not based on any emerging safety concerns from the Phase 3 clinical studies with fulranumab," the company stated.

And that was it.

Five years ago, J&J's osteoarthritis pain drug was in one of the hottest R&D races in the industry. Like Pfizer's ($PFE) tanezumab and Regeneron's ($REGN) fasinumab, the drug targets nerve growth factor to silence pain. But the drug worked too well, leading patients in the studies to blow out their joints and triggering a clinical hold for the class at the FDA.

But the big biopharma groups never lost their appetite for anti-NGFs. Eli Lilly signed up for a $1.8 billion partnership with Pfizer in 2013, with a $200 million upfront they paid in early 2015, when the agency lifted their hold and gave the field a green light to renew their work. Regeneron, meanwhile, inked a $325 million Asia pact last fall with Mitsubishi Tanabe on their anti-NGF, fasinumab (REGN475).

I asked J&J why they would simply hand over the drug at this stage, but a spokesperson merely repeated back the same line the company used in the release. Amgen, meanwhile, tells me they are considering their options.  

- here's the release

Suggested Articles

Chugai Pharmaceuticals is shelling out ¥127.3 billion on a new R&D site in Yokohama, where it will combine the work of two research labs in nearby cities.

The study linked QVM149 to statistically significant improvements in lung function, leading Novartis to talk up its mooted blockbuster. 

The takeover will give Amgen control of a drug discovery platform that landed Nuevolution deals with leading companies.